Clinical trials: Locally Advanced Colorectal Cancer
Rectal Cancer, Neoplasm Metastasis
A Study of Preoperative Radiation Therapy and Capecitabine in Locally Advanced Rectal Cancer
The purpose of this trial is to study the efficacy of preoperative radiation therapy and capecitabine in locally advanced rectal cancer.
- Trial name
- NCT00122291
- Testing
- Capecitabine, Pelvic radiation
- Where
- Canada
- Volunteers
- 66 people
- Sponsor
- Alberta Health services
Colorectal Cancer
Bevacizumab Plus Fluorouracil and Leucovorin in Treating Patients With Locally Advanced or Metastatic Stage IV Colorectal Cancer That Has Progressed After Standard Chemotherapy
RATIONALE: Bevacizumab may stop the growth of tumor cells by blocking the enzymes necessary for cancer cell growth. Drugs used in chemotherapy such as fluorouracil and leucovorin use different ways to stop tumor cells from…
- Trial name
- NCT00066846
- Testing
- bevacizumab, fluorouracil, leucovorin calcium
- Where
- 33 sites in United States
- Sponsor
- National Cancer Institute (NCI)
Rectal Cancer
Preoperative Combined Radiochemotherapy for Patients With Rectal Carcinoma
Rate of T-downstaging (Reduction of the T-stadium) at the time of final surgery following the preoperative combined radiochemotherapy (chemotherapy: Oxaliplatin, Capecitabine) Evaluation of the toxicity grade III and IV of the…
- Trial name
- NCT00297141
- Testing
- Capecitabine, Oxaliplatin
- Where
- 8 sites in Austria
- Volunteers
- 60 people
- Sponsor
- Austrian Breast & Colorectal Cancer Study Group
Rectal Adenocarcinoma, High-risk Locally Advanced
A Multicenter, Randomized Controlled Phase II Study of Short-Course Radiotherapy Followed by Sequential PD-1 Inhibitor and FOLFOX Chemotherapy Versus Long-Course Chemoradiotherapy for High-Risk Locally Advanced pMMR/MSS Lower Rectal Adenocarcinoma (STAR Trial)
This study adopts a prospective randomized controlled design to evaluate the efficacy and safety of short-course radiotherapy followed by sequential PD-1 inhibitor and FOLFOX chemotherapy versus conventional regimens in high-risk…
- Conditions
- Rectal Adenocarcinoma, High-risk Locally Advanced, Short-course Radiotherapy (SCRT), Immunotherapy
- Trial name
- STAR (NCT07669220)
- Testing
- Short-course Radiotherapy, SCRT, Toripalimab
- Where
- China
- Volunteers
- 76 people
- Sponsor
- Sixth Affiliated Hospital, Sun Yat-sen University
Gastrointestinal Tumor
A Study of BL-B01D1 in Patients With Locally Advanced or Metastatic Gastrointestinal Tumor and Other Solid Tumor
In phase Ia study, the safety and tolerability of BL-B01D1 in patients with locally advanced or metastatic gastrointestinal tumor and other solid tumor will be investigated to determine the dose-limiting toxicity (DLT), maximum…
- Trial name
- NCT05262491
- Testing
- BL-B01D1
- Where
- 6 sites in China
- Volunteers
- 96 people
- Sponsor
- Sichuan Baili Pharmaceutical Co., Ltd.
Rectal Cancer
Study of High-Dose-Rate Endorectal Brachytherapy (HDRBT) in the Treatment of Locally Advanced Low Rectal Cancer
This research is being done to see how effective high-dose rate endorectal brachytherapy (HDRBT) is in treating cancer of the lowest part of the bowel (rectum).
- Trial name
- HDRBT (NCT01226979)
- Testing
- High-dose endorectal brachytherapy (HDRBT)
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Colorectal Cancer (MSI-H)
Neoadjuvant Immunotherapy ± Radiotherapy in MSI-H/dMMR Locally Advanced Colorectal Cancer
This phase II clinical trial evaluates the efficacy and safety of three neoadjuvant regimens in patients with locally advanced microsatellite instability-high/mismatch repair-deficient (MSI-H/dMMR) colorectal cancer (CRC): 1)…
- Trial name
- TORCH-OPTIMA (NCT07403877)
- Testing
- Nivolumab, Ipilimumab (1mg/kg), PULSAR
- Where
- China
- Volunteers
- 114 people
- Sponsor
- Fudan University
Rectal Cancer, Locally Advanced
SCRT Sequential Penpulimab in Combination With CAPEOX in the Neoadjuvant Treatment of MSS Locally Advanced Rectal Cancer
The goal of this phase 2 study is to learn about the efficacy and safety of short-course radiotherapy (SCRT) sequential Penpulimab in combination with CAPEOX in the neoadjuvant treatment of microsatellite stable (MSS) locally…
- Trial name
- SPARC (NCT05576480)
- Testing
- Short-course radiotherapy, Penpulimab, CAPEOX
- Where
- China
- Volunteers
- 55 people
- Sponsor
- Ruijin Hospital
Urothelial Carcinoma, Renal Cell Carcinoma
Study of Cabozantinib Alone or in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors
This is a multicenter Phase 1b, open-label study to assess safety, tolerability, preliminary efficacy, and pharmacokinetics (PK) of cabozantinib taken in combination with atezolizumab in subjects with multiple tumor types…
- Conditions
- Urothelial Carcinoma, Renal Cell Carcinoma, Non-Small Cell Lung Cancer, Castration-resistant Prostate Cancer
- Trial name
- NCT03170960
- Testing
- cabozantinib, atezolizumab
- Where
- 124 sites in United States, Australia and 7 more
- Volunteers
- 914 people
- Sponsor
- Exelixis
Rectal Cancer Patients, Rectal Cancer Stage II
Clinical Trial of Neoadjuvant mFOLFOX Plus Alvenor for LARC Patients With High YWHAB Expression
This study is a prospective, multicenter, open-label, randomized controlled Phase II clinical trial enrolling patients with locally advanced rectal cancer who tested positive for YWHAB (tyrosine 3-monooxygenase/tryptophan…
- Conditions
- Rectal Cancer Patients, Rectal Cancer Stage II, Rectal Cancer Stage III
- Trial name
- NCT07176182
- Testing
- mFOLFOX regimen combined with Citrus Flavone Tablets (Alvenor) neoadjuvant treatment group, mFOLFOX regimen neoadjuvant therapy group
- Where
- China
- Volunteers
- 236 people
- Sponsor
- Sixth Affiliated Hospital, Sun Yat-sen University
Anal Cancer
Combination Chemotherapy Plus Radiation Therapy in Treating Patients With Stage II or Stage III Anal Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage tumor cells.
- Trial name
- NCT00003652
- Testing
- cisplatin, fluorouracil, neoadjuvant therapy
- Where
- 48 sites in France
- Volunteers
- 350 people
- Sponsor
- UNICANCER
Breast Cancer, Colorectal Cancer
Phase I Study of CDX-1307, hCG-B Vaccine, for Patients With Incurable, Locally Advanced or Metastatic Breast, Colorectal, Pancreatic, Bladder or Ovarian Cancer
This research study is for individuals who have advanced breast, colon, pancreatic, ovarian or bladder cancer. Celldex Therapeutics, Inc.
- Conditions
- Breast Cancer, Colorectal Cancer, Pancreatic Cancer, Bladder Cancer
- Trial name
- CDX1307-02 (NCT00648102)
- Testing
- CDX-1307
- Where
- 3 sites in United States
- Volunteers
- 36 people
- Sponsor
- Celldex Therapeutics
Colon Cancer, Colorectal Cancer
Chemotherapy Administered Every 2 Weeks With or Without Pegfilgrastim in Subjects With Advanced or Metastatic Colon Cancer
The purpose of this research study is to evaluate the safety and effectiveness of pegfilgrastim in reducing grade 3/4 neutropenia when given after one of three chemotherapy regimens (FOIL, FOLFOX or FOLFIRI) in patients with…
- Conditions
- Colon Cancer, Colorectal Cancer, Rectal Cancer
- Trial name
- NCT00094809
- Testing
- Pegfilgrastim
- Volunteers
- 252 people
- Sponsor
- Amgen
Rectal Cancer
IMMUNOlogical Microenvironment in REctal Adenocarcinoma Treatment.
Background The current management on rectal cancer based on TNM staging has some limitations. In locally advanced rectal cancer after neoadjuvant therapy the persistence of a complete response to therapy cannot be accurately…
- Trial name
- IMMUNOREACT2 (NCT04917263)
- Testing
- Immunohistochemistry, Flow citometry, Trascriptome analysis
- Where
- Italy
- Volunteers
- 544 people
- Sponsor
- University of Padova
Colorectal Cancer
SU5416 in Treating Patients With Metastatic or Locally Recurrent Colorectal Cancer
Phase II trial to study the effectiveness of SU5416 in treating patients who have metastatic or locally recurrent colorectal cancer. SU5416 may stop the growth of colorectal cancer by stopping blood flow to the tumor.
- Trial name
- NCT00006001
- Testing
- semaxanib
- Where
- 10 sites in United States
- Volunteers
- 37 people
- Sponsor
- National Cancer Institute (NCI)
Rectum Cancer, Adenocarcinoma
ADAR1 Expression Level in Rectal Cancer
Total neoadjuvant therapy (TNT) is currently the standard treatment for locally/locally advanced rectal cancer due to better response and fewer distant metastases.
- Trial name
- ADAR1TNT (NCT07108348)
- Testing
- Adenosine deaminase acting on RNA1
- Where
- Turkey (Türkiye)
- Volunteers
- 50 people
- Sponsor
- Necmettin Erbakan University
Metastatic Colorectal Cancer
Triplet (FOLFOXIRI) vs. Doublet (FOLFOX or FOLFIRI) Regimen as a 1st Line Treatment in Metastatic Colorectal Carcinoma
This is a prospective randomized phase II trial was done in clinical oncology department at Kasr Alainy hospital, Cairo university (NEMROCK) to evaluate the role of intensification of chemotherapy in the first line for treatment…
- Trial name
- NCT05316818
- Testing
- FOLFOXIRI Protocol
- Where
- Egypt
- Volunteers
- 64 people
- Sponsor
- Kasr El Aini Hospital
Rectal Cancer
Trial of Nivolumab With FOLFOX After Chemoradiation in Rectal Cancer Patients
This is a phase II, prospective, open label, one-center study for evaluation of the addition of nivolumab to the chemotherapy phase of the neoadjuvant treatment for locally advanced rectal cancer patients.
- Trial name
- NCT03921684
- Testing
- Capecitabine, Radiation therapy, mFOLFOX6
- Where
- Israel
- Volunteers
- 29 people
- Sponsor
- Baruch Brenner
Rectal Cancer, Neoadjuvant Therapy
Interval Between Neoadjuvant Therapy and Surgery in the Treatment of Locally Advanced Rectal Cancer (CRONOS)
The investigators evaluate the response of rectal cancer to neoadjuvant therapy and classify the response according to specific periods of time after the end of neoadjuvant treatment.
- Trial name
- CRONOS (NCT04717947)
- Testing
- Interval between NAT and surgery
- Where
- Spain
- Volunteers
- 911 people
- Sponsor
- Hospital Clinic of Barcelona
Rectal Cancer, Locally Advanced Rectal Carcinoma
MRI T1 Relaxation Time in Rectal Cancer
The goal of this observational study is to learn about the T1 relaxation time and T1 relaxation time properties of the disease in people with locally advanced rectal cancer.
- Trial name
- NCT05876026
- Where
- Denmark
- Volunteers
- 44 people
- Sponsor
- Vejle Hospital